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Background/Aims: The frequency of nontuberculous mycobacteria pulmonary disease in HIV-negative patients is
increasing; the most common pathogen in Korea is the Mycobacterium avium complex (MAC). However, few stud-
ies have evaluated the treatment outcome of MAC pulmonary disease in Korea. 
Methods: The efficacy of a clarithromycin-containing regimen for MAC pulmonary disease was studied in 42
patients treated for more than 6 months between January 2005 and December 2008. All patients were treated
with a regimen consisting of clarithromycin, rifampin, and ethambutol. Streptomycin was added in 10 patients. 
Results: Among the 42 patients, a negative culture conversion was achieved in 33 (78.6%), and the median
duration of treatment in these patients was 19 months (interquartile range [IQR], 16 to 22). Of the 33 patients
with a negative culture conversion, 14 completed treatment. During the follow-up period (median, 10 months;
IQR, 4 to 20) for the 14 patients, one relapsed at 24 months after treatment completion. The culture conversion
rate was significantly higher in patients who were treated with more than 500 mg/day clarithromycin (87.1% vs.
54.5%, p = 0.038). 
Conclusions: The combined regimen including clarithromycin was effective against MAC pulmonary disease.
High-dose clarithromycin of more than 500 mg/day may improve the outcome of patients with MAC pulmonary
disease. (Korean J Intern Med 2011;26:54-59)
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INTRODUCTION
Mycobacterium avium complex (MAC) is the most
common pathogen of nontuberculous mycobacterial pul-
monary diseases in Korea [1-4]. Recently, the frequency of
this infection has been increasing [1,2,5]. The American
Thoracic Society (ATS)/Infectious Disease Society of
America (IDSA) has recommended a combination drug
regimen including clarithromycin or azithromycin,
rifampin or rifabutin, and ethambutol for treating MAC
pulmonary disease in human immunodeficiency virus
(HIV)-negative patients [6]. Streptomycin has been rec-
ommended for  patients with severe and advanced, espe-
cially fibrocavitary, disease or previously treated disease
[6]. The Korean Academy of Tuberculosis and Respiratory
Diseases has recommended a similar regimen in their
2005 guidelines of tuberculosis management [7].
However, few studies have been conducted on the treat-
ment outcomes from a combined antibiotic therapy for
MAC pulmonary disease in Korea [8]. Therefore, the effi-
cacy of a clarithromycin-containing regimen for MAC pul-
monary disease was investigated in this study. 
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METHODS
Patients
A retrospective review of the medical records of 123
patients with MAC pulmonary disease, diagnosed using
the 2007 criteria of the ATS, from January 2005 to
December 2008 at Chonnam National University
Hospital in Gwangju, South Korea, was performed.
Permission was obtained from the institutional review
board to review and publish patient records retrospective-
ly. Among the 123 patients, 52 patients who did not
receive treatment, 14 who were transferred to their refer-
ring institutions after diagnosis of MAC pulmonary dis-
ease, and two who died due to causes not attributed to
MAC pulmonary disease were excluded. Thirteen patients
who were treated for less than 6 months were also exclud-
ed. Among these patients, seven were lost to follow-up,
five received combination drug treatment for less than 6
months at the end of the study period, and one refused
treatment. Finally, 42 patients who received combination
drug treatment for more than 6 months were included in
this study. No patient had been previously treated for
MAC pulmonary disease before presenting to this hospi-
tal.
Treatment protocol
All patients were managed according to the 1997 (1) and
2007 (2) guidelines recommended by the ATS. The initial
daily doses were clarithromycin (500-1,000 mg/day),
rifampin (450 mg for body weight ≤ 50 kg or 600 mg for
body weight > 50 kg), and ethambutol (25 mg/kg per day
for 2 months followed by 15 mg/kg per day). Streptomycin
was given intramuscularly to patients with severe or fibro-
cavitary disease at 10-15 mg/kg, three times per week for
the first 3 to 6 months as tolerated. 
Microbiological and radiological evaluation
Sputum smears and mycobacterial cultures were col-
lected using standard methods [9]. M. avium and M.
intracellulare were identified by multiplex polymerase
chain reaction (PCR) assay, as described previously [10].
Amplification for all multiplex PCR reactions was per-
formed in a DNA thermal cycler (GeneAmp PCR 9600,
Perkin-Elmer, Waltham, MA, USA). 
Computed tomography (CT) scans were obtained from
all patients at the start of treatment to evaluate lesions
including cavities and bronchiectasis and underlying pul-
monary conditions. Chest radiographs were obtained ini-
tially and at least every 3 months thereafter. Chest radiog-
raphy and CT scan findings were classified as upper lobe
cavitary or nodular bronchiectatic forms.
Assessment of efficacy
Efficacy was evaluated based on culture conversion rate,
improvement of radiological findings, and clinical symp-
toms. Culture conversion was defined as three consecutive
negative sputum cultures during the treatment period,
with the time of conversion defined as the date of the first
negative culture. Conversion to a negative culture was
assumed if the patient could not expectorate sputum. A
sputum relapse was defined as two consecutive positive
cultures after culture conversion. The clinical symptoms
and radiological findings were compared at the initiation
of treatment and the end of treatment to determine clini-
cal and radiological efficacy; the findings were divided into
three categories including “improvement,” “no change,”
and “aggravation.”
Statistical analyses
All results were presented as the median and interquar-
tile range (IQR) or number and percent because the
majority of the data did not follow a normal distribution.
Categorical variables were analyzed with the Pearson’s
chi-square test or Fisher’s exact test, as appropriate.
Continuous variables were analyzed with the Mann-
Whitney U test. Statistical significance was established at
a p< 0.05.
RESULTS
Patient characteristics
Forty-two patients with MAC pulmonary disease who
had received combination antibiotic therapy for more
than 6 months were included in this study. Among the 42
patients, 25 (60%) were male and 17 (40%) were female.
The median age of the patients was 65 years (range, 55 to
74) (Table 1). Most patients had respiratory symptoms
such as cough (71%), sputum (71%), hemoptysis (24%),
and dyspnea (14%). Fourteen patients had a positive spu-
tum acid-fast bacilli (AFB) smear at the time of the initial
antibiotic treatment. The radiologic classifications includ-
ed 17 (40%) and 25 (60%) patients with upper lobe cavi-
tary and nodular bronchiectatic disease, respectively. Of
the 42 patients, 22 (52%) had a history of antituberculosis
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Antibiotic treatment
The median duration of treatment was 18 months (IQR,
13 to 22). The dose of CAM (clarithromycin) dose was
1,000 mg/day for 30 patients, 750 mg/day for one patient,
500 mg/day for 10 patients, and 250 mg/day for one
patient. Streptomycin was given to six (14%) patients for a
median of 3 months (IQR, 2 to 8).
Of the 42 patients, 21 (50%) completed the combined
treatment. Among the 21 patients who did not complete
the treatment course, three were transferred to another
hospital at 13, 15, and 22 months of combined treatment,
and one patient was lost to follow-up after 16 months of
combined treatment. The remaining 17 patients continued
to be treated until the end of the study period. 
Treatment outcome
The overall culture conversion rate was 78.6% (33/42),
and the median time to culture conversion was 49 days
(IQR, 28 to 77). Of the 42 patients, 21 (50%) completed
the combined treatment. Among the 21 patients who com-
pleted treatment, 14 (67%) achieved culture conversion
and continued to have a negative conversion for a median
of 10 months (IQR, 4 to 20) during follow-up. One patient
relapsed at 24 months after treatment completion. No sig-
nificant difference was observed between patients with
and without treatment completion with regard to clinical
characteristics such as age (p = 0.970), body mass index
(BMI; p = 0.755), positive sputum AFB smear at the start
of treatment (p = 0.197), or type of disease (p = 0.753).
However, treatment duration was significantly longer in
patients that completed treatment (median, 20 months;
IQR, 19 to 24 months) compared with patients that did
not complete treatment (median, 16 months; IQR, 15 to
20 months) (p= 0.006). 
Twenty-two (52%) patients showed improvement on
radiologic findings, 15 (36%) were unchanged, and five
(12%) had aggravated disease. Symptoms were evaluated
among 33 patients by medical chart review; 12 (36%) were
improved, 18 (55%) were unchanged, and three (9%) had
aggravated symptoms. 
Patients with upper lobe cavitary disease had signifi-
cantly lower culture conversion rates compared with
patients with nodular bronchiectatic disease (30% vs.
70%, p = 0.019). Radiologic and symptomatic responses
were significantly better in the patients who underwent
culture conversion. No significant differences in age, gen-
der, BMI, sputum AFB smear, or duration of treatment
were observed between patients who did and did not
undergo culture conversion (Table 2). 
The culture conversion rate was significantly higher in
patients who received more than 500 mg/day of clar-
ithromycin (87.1%) than in patients who received less
than 500 mg/day of clarithromycin (54.5%, p = 0.038).
The radiologic findings showed also significantly higher
rates of improvement in patients who received more than
500 mg/day of clarithromycin than in patients who
received less than 500 mg/day of clarithromycin (61% vs.
27%, p = 0.016). Symptomatic improvement tended to be
better in patients who received more than 500 mg/day of
clarithromycin than in patients who received less than
500 mg/day, although the difference was not statistically
significant (46% vs. 11%, p = 0.129). No significant differ-
ences in age, gender, BMI, sputum AFB smear, duration
of treatment, or use of streptomycin were observed
between patients who received more than 500 mg/day of
clarithromycin and those who received less than 500
mg/day (data not shown).
Adverse effects
Gastrointestinal symptoms (e.g., anorexia, nausea, dys-
pepsia, and diarrhea) associated with the combined
Table 1. Baseline characteristics of the 42 patients
with MAC pulmonary disease
Characteristics Total (n = 42)
Age, yr 65 (55 - 74)
Gender, male 25 (60)
Body mass index, kg/m2 18.8 (17.7 - 22.1)
Smoking history
Non-smoker 22
Ex-smoker 14
Current smoker 6
Respiratory symptoms
Cough 30 (71)
Sputum 30 (71)
Hemoptysis 10 (24)
Dyspnea 6 (14)
Positive sputum AFB smear 14 (33)
Type of disease
Upper lobe cavitary form 17 (40)
Nodular bronchiectatic form 25 (60)
Etiology
M. avium 10 (24)
M. intracellulare 32 (76)
Values are presented as number (%) or median (interquartile range).
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antibiotic treatment developed in four (9.5%) patients. In
these four patients, three continued clarithromycin with-
out a dose reduction due to mild symptoms. One patient
had to reduce the dose of clarithromycin from 1,000
mg/day to 500 mg/day. Two (5%) patients discontinued
ethambutol because of optic neuritis. 
DISCUSSION
The treatment outcome of MAC pulmonary disease
was disappointing before the use of newer macrolide
antibiotics such as clarithromycin and azithromycin [6].
Since 1990, the introduction of newer macrolide antibi-
otics, treatment of pulmonary MAC disease has improved
patient outcome [11,12]. Wallace et al. [12] reported on
clinical trials using a clarithromycin-containing regimen
including clarithromycin, ethambutol, rifabutin or
rifampin, and initial treatment with streptomycin; the
regimen achieved a greater than 90% culture conversion
rate. However, the culture conversion rate was 64% when
the patients who dropped out of the treatment trial and
those who relapsed were included. Most other studies
using the macrolide-containing regimen showed a similar
culture conversion rate [13]. 
In the present study, the combined therapy including
clarithromycin achieved a 79% culture conversion rate
after excluding patients who received the treatment for
less than 6 months. This is a relatively high treatment
response compared to other studies; however, if the
patients who were lost to follow up (n = 7) and those who
refused treatment (n = 1) were included, the culture con-
version rate was 66% (33/50). Therefore, the treatment
outcome in this study was consistent with previous stud-
ies. In a Korean study [8], culture conversion rates with a
clarithromycin-containing regimen were only 60%
(9/15). If the patients who dropped out and relapsed
were included, the culture conversion rate was lower than
60%, relatively lower than that in our study. Higher spu-
tum smear positive rates at the start of treatment in their
study compared with those in our study (87% vs. 33%)
suggest that patients in their study had more severe dis-
ease than those in our study. However, that study may
not be generalizable, because only 15 patients enrolled
Table 2. Characteristics of the 42 patients with or without culture conversion to negative  
Culture negative conversion  Persistent positive  p value
(n = 33) (n = 9)
Age, yr 65 (55 - 74) 68 (55 - 74) 0.471
Gender, male 18 (55) 7 (78) 0.271
Body mass index, kg/m2 18.8 (18.0 - 22.1) 18.0 (16.2 - 23.3) 0.457
Positive sputum AFB smear 11 (33) 3 (38) 1.000
Type of disease
Upper lobe cavitary form 10 (30) 7 (78) 0.019
Nodular bronchiectatic form 23 (70) 2 (22)
Duration of treatment, mon 18.0 (13.0 - 20.0) 19.0 (12.5 - 24.5) 0.414
Dose of clarithromycin, mg/day
≤ 500  6 (18) 5 (56) 0.038
> 500  27 (82) 4 (44)
Use of streptomycin 3 (9) 3 (33) 0.101
Radiographic response
Improvement 22 (67) 0 (0) < 0.001
No change 11 (33) 4 (44)
Aggravation 0 (0) 5 (56)
Symptomatic response 
Improvement 12 (46) 0 (0) 0.018
No change 13 (50) 5 (71)
Aggravation 1 (4) 2 (29)
Values are presented as number (%) or median (interquartile range). 
Fisher’s exact test or Mann-Whitney U test was performed as appropriate.
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and 33% (5/15) of all patients received treatment for less
than 12 months. 
The side effects of clarithromycin such as gastrointesti-
nal irritation and hepatotoxicity could limit the long-term
use of this drug, especially in elderly patients [14]. Recent
ATS/IDSA guidelines suggest reducing the dose of clar-
ithromycin (500 mg/day or 250 mg twice) in patients
with advanced age or a small body mass [6]. However,
the efficacy of different doses of clarithromycin has not
been well studied. Clarithromycin had an inhibitory effect
on bacterial growth at a sub-inhibitory concentration in
an in vitro study [15] and higher doses of clarithromycin
showed higher concentrations in the bronchial epithelial
lining fluid in a human study [16]. Two clinical trials with
a limited number of enrolled patients showed similar
results. Kobashi and Matsushima [17] reported that high-
er doses of clarithromycin (600 mg/day vs. 400 mg/day)
resulted in a higher sputum conversion rate in patients
with MAC pulmonary disease. Hasegawa et al. [18] also
demonstrated that a higher dose of clarithromycin (800
mg/day vs. 400 mg/day) was better for obtaining culture
conversion. In the present study, more than 500 mg/day
of clarithromycin resulted in significantly higher culture
conversion rates. The previous two studies showed that
the higher dose of clarithromycin did not have signifi-
cantly different rates of adverse events compared to lower
doses [17,18]. In the present study, adverse effects were
not significantly different in the patients who received
less than 500 mg (27%) compared with those who
received more than 500 mg (13%) of clarithromycin (p =
0.353). 
Another factor related to the treatment outcome in this
study was a different type of MAC pulmonary disease.
Upper lobe cavitary disease was associated with a signifi-
cantly lower culture conversion rate compared with the
nodular bronchiectatic form. Although some studies
showed no difference in treatment outcome between cav-
itary disease and non-cavitary disease [19,20], a large
prospective study showed that patients with non-cavitary
disease had a four-times higher (95% confidence interval,
1.74 to 9.19; p = 0.001) culture response rate than
patients with cavitary disease [21]. Therefore, more
aggressive treatment is recommended in patients with
cavitary MAC pulmonary disease than the non-cavitary
form [6]. 
The major limitation of the present study was the retro-
spective study design. The information obtained was lim-
ited to what was available in the medical records.
Furthermore, clarithromycin susceptibility testing was
not performed. Although the ATS/IDSA guidelines  rec-
ommend that previously untreated MAC isolates should
be tested by clarithromycin susceptibility testing [6],
untreated MAC isolates are usually susceptible to clar-
ithromycin [6,22], which might have influenced the treat-
ment outcome data. Moreover, the long-term treatment
outcome could not be evaluated in this study. Half of all
patients did not complete the treatment, and the median
follow-up duration after treatment completion in the
remaining half was only 10 months. Therefore, longer fol-
low-up studies are needed to fully evaluate the long-term
outcome of MAC pulmonary disease.
In conclusion, a combined treatment consisting of clar-
ithromycin, rifampin, and ethambutol with or without
the initial use of streptomycin was effective for previously
untreated MAC pulmonary disease. High dose
claithromycin, more than 500 mg/day, may improve the
treatment outcome of MAC pulmonary disease. 
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